RxDoctor Payments Data

Daniel Chagin, MD

Family Medicine · Cleveland, OHNPI 1407863152

Payments from drug & device makers

$3,144in general payments, 2019–2025

Across 56 payments — averaging $56.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$969
  • Biohaven Pharmaceutical Holding Company Ltd.$450
  • Boehringer Ingelheim$356
  • AbbVie$227
  • Sanofi-aventis U.S. LLC$215
  • Coloplast$174
  • plus $752 from 9 others

What the payments were for

  • Food & beverage$3,12399%
  • Education$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,144 in reported general payments places this provider in the 80th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$54,125
Medicare patients
195
Services billed
850

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide105$158,132
JardianceEmpagliflozin151$145,007
XareltoRivaroxaban103$99,215
MounjaroTirzepatide41$66,737
EliquisApixaban63$51,602
Dupixent SyringeDupilumab12$44,528
Nurtec OdtRimegepant Sulfate36$35,339
TrulicityDulaglutide31$28,515
JanuviaSitagliptin Phosphate38$25,657
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate55$15,698
TradjentaLinagliptin11$15,148
LinzessLinaclotide14$13,186
SymbicortBudesonide/Formoterol Fumarate36$12,228
Spiriva HandihalerTiotropium Bromide19$12,014
Tiotropium Bromide25$10,621

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$356$160,155162 claims
Novo NordiskOzempic$122$158,132105 claims
Johnson & JohnsonXarelto$150$99,215103 claims
Lilly USA, LLCMounjaro, Trulicity$125$95,25272 claims
PfizerEliquis, Nurtec Odt$114$86,94199 claims
AbbVieLinzess, Synthroid$227$15,77342 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →